Back to results
CompletedPhase 2

Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer

NCT04508803

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Fudan University Shanghai Cancer center

Shanghai, China

View on ClinicalTrials.gov
Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer — TrialFind